A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kanzaki, Hiroyuki ^a,b   Shinohara, Fumiaki ^c   Suzuki, Maiko ^d,e   Wada, Satoshi ^a   Miyamoto, Yutaka ^a   Yamaguchi, Yuuki ^a   Katsumata, Yuta ^a   Makihira, Seicho ^c   Kawai, Toshi ^d,f   Taubman, Martin A ^d   Nakamura, Yoshiki ^a  

^a TSURUMI UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c FORSYTH INSTITUTE   (United States)

^d Department Mineralized Tissue Biology ^*  (United States)

^e KYUSHU UNIVERSITY   (Japan)

^f HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CULTURE; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; MCF-7 CELL LINE; METABOLISM; MOUSE; PATHOLOGY; PROTEIN DEGRADATION; RAW 264.7 CELL LINE; RNA INTERFERENCE; T LYMPHOCYTE; TUMOR CELL LINE;

ADAM17 PROTEIN; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; INTERFERON-GAMMA; MCF-7 CELLS; MICE; MICE, INBRED BALB C; PROTEOLYSIS; RAW 264.7 CELLS; RECOMBINANT PROTEINS; RNA INTERFERENCE; T-LYMPHOCYTES;

EID: 84985943457     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32259     Document Type: Article

References (50)

1. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nature reviews. Immunology 6, 836-848, doi: 10.1038/nri1961 (2006).
2. Smyth, M. J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature reviews. Cancer 2, 850-861, doi: 10.1038/nrc928 (2002).
3. Pestka, S., Krause, C. D. & Walter, M. R. Interferons, interferon-like cytokines, and their receptors. Immunological reviews 202, 8-32, doi: 10.1111/j.0105-2896.2004.00204.x (2004).
4. Kaplan, D. H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 95, 7556-7561 (1998).
5. Ishikawa, T. et al. Whole blood interferon-gamma levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. International journal of cancer. Journal international du cancer, doi: 10.1002/ijc.28117 (2013).
6. Gerber, S. A. et al. IFN-gamma Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor. The American journal of pathology, doi: 10.1016/j.ajpath.2013.02.041 (2013).
7. Xie, F. J. et al. Adenovirus-mediated interferon-gamma gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo. Anatomical record (Hoboken, N.J.: 2007) 296, 604-610, doi: 10.1002/ar.22661 (2013).
8. Hastie, C. Interferon gamma, a possible therapeutic approach for late-stage prostate cancer? Anticancer research 28, 2843-2849 (2008).
9. Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408, 600-605, doi: 10.1038/35046102 (2000).
10. Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Advances in immunology 96, 41-101, doi: 10.1016/s0065-2776(07)96002-2 (2007).
11. Khabar, K. S. & Young, H. A. Post-transcriptional control of the interferon system. Biochimie 89, 761-769, doi: 10.1016/j. biochi.2007.02.008 (2007).
12. Kosuge, T., Tamura, T., Nariuchi, H. & Toyoshima, S. Effect of inhibitors of glycoprotein processing on cytokine secretion and production in anti CD3-stimulated T cells. Biological & pharmaceutical bulletin 23, 1-5 (2000).
13. Kosuge, T. & Toyoshima, S. Increased degradation of newly synthesized interferon-gamma (IFN-gamma) in anti CD3-stimulated lymphocytes treated with glycoprotein processing inhibitors. Biological & pharmaceutical bulletin 23, 545-548 (2000).
14. Celada, A. & Schreiber, R. D. Internalization and degradation of receptor-bound interferon-gamma by murine macrophages. Demonstration of receptor recycling. Journal of immunology (Baltimore, Md.: 1950) 139, 147-153 (1987).
15. Anderson, P., Yip, Y. K. & Vilcek, J. Human interferon-gamma is internalized and degraded by cultured fibroblasts. The Journal of biological chemistry 258, 6497-6502 (1983).
16. Farnault, L., Sanchez, C., Baier, C., Le Treut, T. & Costello, R. T. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clinical & developmental immunology 2012, 421702, doi: 10.1155/2012/421702 (2012).
17. Topfer, K. et al. Tumor evasion from T cell surveillance. Journal of biomedicine & biotechnology 2011, 918471, doi: 10.1155/2011/918471 (2011).
18. Groth, A., Kloss, S., von Strandmann, E. P., Koehl, U. & Koch, J. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. Journal of innate immunity 3, 344-354, doi: 10.1159/000327014 (2011).
19. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (New York, N.Y.) 331, 1565-1570, doi: 10.1126/science.1203486 (2011).
20. Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1, 447-456 (1994).
21. Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annual review of immunology 29, 235-271, doi: 10.1146/annurev-immunol-031210-101324 (2011).
22. Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111, doi: 10.1038/35074122 (2001).
23. Mundy, G. R. Mechanisms of bone metastasis. Cancer 80, 1546-1556 (1997).
24. Orr, F. W., Sanchez-Sweatman, O. H., Kostenuik, P. & Singh, G. Tumor-bone interactions in skeletal metastasis. Clinical orthopaedics and related research, 19-33 (1995).
25. Yoneda, T., Sasaki, A. & Mundy, G. R. Osteolytic bone metastasis in breast cancer. Breast cancer research and treatment 32, 73-84 (1994).
26. Saftig, P. & Reiss, K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? European journal of cell biology 90, 527-535, doi: 10.1016/j.ejcb.2010.11.005 (2011).
27. Arribas, J. & Esselens, C. ADAM17 as a therapeutic target in multiple diseases. Current pharmaceutical design 15, 2319-2335 (2009).
28. Pruessmeyer, J. & Ludwig, A. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Seminars in cell & developmental biology 20, 164-174, doi: 10.1016/j.semcdb.2008.09.005 (2009).
29. McGowan, P. M. et al. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 2335-2343, doi: 10.1158/1078-0432.ccr-06-2092 (2007).
30. Rocks, N. et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). British journal of cancer 94, 724-730, doi: 10.1038/sj.bjc.6602990 (2006).
31. Ko, S. Y. et al. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer letters 245, 33-43, doi: 10.1016/j.canlet.2005.10.019 (2007).
32. Ohtsuka, T. et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. International journal of cancer. Journal international du cancer 118, 263-273, doi: 10.1002/ijc.21324 (2006).
33. Mochizuki, S. & Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer science 98, 621-628, doi: 10.1111/j. 1349-7006.2007.00434.x (2007).
34. Pang, K. R., Wu, J. J., Huang, D. B., Tyring, S. K. & Baron, S. Biological and clinical basis for molecular studies of interferons. Methods in molecular medicine 116, 1-23, doi: 10.1385/1-59259-939-7:1 (2005).
35. Black, R. A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733, doi: 10.1038/385729a0 (1997).
36. Lum, L. et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. The Journal of biological chemistry 274, 13613-13618 (1999).
37. Kanzaki, H., Han, X., Lin, X., Kawai, T. & Taubman, M. In Interface Oral Health Science 2009 (eds Takashi Sasano & Osamu Suzuki) Ch. 115, 403-405 (Springer, Japan, 2010).
38. Roodman, G. D. Mechanisms of bone metastasis. The New England journal of medicine 350, 1655-1664, doi: 10.1056/NEJMra030831 (2004).
39. Blair, J. M., Zhou, H., Seibel, M. J. & Dunstan, C. R. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature clinical practice. Oncology 3, 41-49, doi: 10.1038/ncponc0381 (2006).
40. Lipton, A. & Goessl, C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 48, 96-99, doi: 10.1016/j.bone.2010.10.161 (2011).
41. Iba, K., Takada, J. & Yamashita, T. [Prospects of treatment using interferon for bone diseases]. Nihon rinsho. Japanese journal of clinical medicine 64, 1275-1280 (2006).
42. Rawlings, N. D., Barrett, A. J. & Bateman, A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic acids research 40, D343-D350, doi: 10.1093/nar/gkr987 (2012).
43. Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science (New York, N.Y.) 282, 1281-1284 (1998).
44. Asai, M. et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochemical and biophysical research communications 301, 231-235 (2003).
45. Gschwind, A., Hart, S., Fischer, O. M. & Ullrich, A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. The EMBO journal 22, 2411-2421, doi: 10.1093/emboj/cdg231 (2003).
46. Schramme, A., Abdel-Bakky, M. S., Kampfer-Kolb, N., Pfeilschifter, J. & Gutwein, P. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. Biochemical and biophysical research communications 370, 311-316, doi: 10.1016/j.bbrc.2008.03.088 (2008).
47. Engel, J. B. et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Archives of gynecology and obstetrics 289, 141-147, doi: 10.1007/s00404-013-2922-9 (2014).
48. Fiorucci, S. et al. TNFalpha processing enzyme inhibitors prevent aspirin-induced TNFalpha release and protect against gastric mucosal injury in rats. Alimentary pharmacology & therapeutics 12, 1139-1153 (1998).
49. Kanzaki, H. et al. In Interface Oral Health Science 2011 (eds Keiichi Sasaki, Osamu Suzuki & Nobuhiro Takahashi) Ch. 45, 173-175 (Springer, Japan, 2012).
50. Kanzaki, H., Shinohara, F., Kajiya, M. & Kodama, T. The Keap1/Nrf2 Protein Axis Plays a Role in Osteoclast Differentiation by Regulating Intracellular Reactive Oxygen Species Signaling. Journal of Biological Chemistry 288, 23009-23020, doi: 10.1074/jbc. M113.478545 (2013).